Recombinant version of CRT trademarked famous anti-CD3 monoclonal antibody, capable of differentiating between T vs B cells lymphomas and leukaemias. Background and Research Application The CD3 complex, composed of four distinct CD3 polypeptide chains ( CD3gamma, CD3omega and 2X CD3episilon), associates with the T cell antigen receptor (TCR). It is found on all mature human […]
| Inventor | Institute |
|---|---|
| Peter Beverley | Cancer Research, UK London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 152589 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction;Immunology;Stem cell biology |
| Application: | FACS ; WB |
| Target: | CD3 |
| Reactivity: | Human |
| Clone: | rUCH-T1 |
| Host: | Mouse |
| Class: | Recombinant |
| Product description: | Recombinant version of CRT trademarked famous anti-CD3 monoclonal antibody, capable of differentiating between T vs B cells lymphomas and leukaemias. Background and Research Application The CD3 complex, composed of four distinct CD3 polypeptide chains ( CD3gamma, CD3omega and 2X CD3epsilon), associates with the T cell antigen receptor (TCR). It is found on all mature human T lymphocytes, NK cells and some thymocytes. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction. This is a recombinant version of anti-CD3 UCH-T1 . UCH-T1 is considered a pan T-cell marker – it can be used for the detection of T cell populations in peripheral blood and lymph nodes and the categorisation of T versus B cell lymphomas and leukaemias. It reacts with the majority of peripheral blood T lymphocytes, a major proportion of thymocytes, the majority of T cell chronic lymphocytic leukaemia cells, Sezary leukaemias and approximately 70% of acute lymphoblastic leukaemias of T cell origin. It can also be used to study the role of CD3 in TCR signal transduction events. This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with UCHT1 being one of the first successful fusions. |
|---|---|
| Additional notes: | UCH-T1TM is a registered trademark of Cancer Research Technology, Limited. All rights reserved. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Human infant thymocytes and Sezary cells. |
| Immunogen Uniprot ID: | P04234 |
| Target background: | Recombinant version of CRT trademarked famous anti-CD3 monoclonal antibody, capable of differentiating between T vs B cells lymphomas and leukaemia's.Background and Research Application The CD3 complex, composed of four distinct CD3 polypeptide chains (CD3γ, CD3δ and 2X CD3Ɛ), associates with the T cell antigen receptor (TCR). It is found on all mature human T lymphocytes, NK cells and some thymocytes. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction.This is a recombinant version of anti-CD3 UCH-T1. UCH-T1 is considered a pan T-cell marker – it can be used for the detection of T cell populations in peripheral blood and lymph nodes and the categorisation of T versus B cell lymphomas and leukaemia's. It reacts with the majority of peripheral blood T lymphocytes, a major proportion of thymocytes, the majority of T cell chronic lymphocytic leukaemia cells, Szary leukaemia's and approximately 70% of acute lymphoblastic leukaemia's of T cell origin. It can also be used to study the role of CD3 in TCR signal transduction events.This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with UCHT1 being one of the first successful fusions. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS only |
| Storage conditions: | Store at -20 C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Original hybridoma first published in: Beverley et al. 1981. Eur J Immunol. 11(4):329-34. PMID: 6788570. Distinctive Fn characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.